Economics of vaccines revisited

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1139-1141

  Postma, Maarten J ^a   Standaert, Baudouin A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness; Health economics; Modelling; New approaches; Perspectives

Indexed keywords

NEW DRUG; VACCINE;

COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; HEALTH CARE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; IMMUNOGENICITY; MEDICAL DECISION MAKING; NOTE; VACCINATION;

COST-EFFECTIVENESS; HEALTH ECONOMICS; MODELING; NEW APPROACHES; PERSPECTIVES;

COSTS AND COST ANALYSIS; HUMANS; VACCINATION; VACCINES;

EID: 84877589021     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23447     Document Type: Note

References (27)

1. Ethgen O, Standaert B. Population- versus cohort-based modelling approaches. Pharmacoeconomics 2012; 30:171-81; PMID:22283692; http://dx.doi.org/10.2165/11593050-000000000-00000.
2. Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 2012; 15:562-7; PMID:22583467; http://dx.doi.org/10.1016/j.jval.2012.01.005.
3. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009; 200(Suppl 1):S16-27; PMID:19817595; http://dx.doi.org/10.1086/605026.
4. Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines 2012; 11:1235-47; PMID:23170992; http://dx.doi.org/10.1586/erv.12.99.
5. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2:649-60; PMID:14711326; http://dx.doi.org/10.1586/14760584.2.5.649.
6. Postma MJ, Beardsworth P, Wilschut JC. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes. J Med Econ 2008; 11:743-68; PMID:19450079; http://dx.doi.org/10.3111/13696990802505557.
7. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 2007; 25:5945-57; PMID:17629362; http://dx.doi.org/ 10.1016/j.vaccine.2007.04.070.
8. Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect 2012; 18(Suppl 5):70-6; PMID:22882176; http://dx.doi.org/10.1111/j.1469-0691.2012.03977.x.
9. Smith RD, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ 2009; 339:b4571; PMID:19926697; http://dx.doi.org/10.1136/bmj. b4571.
10. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. Health Econ 2012; In Press; PMID:23080321; http://dx.doi.org/10.1002/hec.2879.
11. Smith RD, Keogh-Brown MR, Barnett T. Estimating the economic impact of pandemic influenza: An application of the computable general equilibrium model to the U.K. Soc Sci Med 2011; 73:235-44; PMID:21708419; http://dx.doi.org/10. 1016/j.socscimed.2011.05.025.
12. PharmacoEconomic Guidlines. 11-12-2012. Ref Type: Internet Communication, www.ispor.org/PEguidelines/index.asp
13. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 2011; 11:462; PMID:21663620; http://dx.doi.org/10.1186/1471-2458-11-462.
14. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2009; 29:33-50; PMID:18948433; http://dx.doi.org/10.1177/0272989X08324955.
15. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. [Corrected Proof.]. Vaccine 2007; 25:3971-9; PMID:17400341; http://dx.doi.org/10.1016/j.vaccine. 2007.02.070.
16. Standaert B, Parez N, Tehard B, Colin X, Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6:199-216; PMID:19382820; http://dx.doi.org/10.1007/ BF03256134.
17. Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27:281-97; PMID:19485425; http://dx.doi.org/10.2165/ 00019053-200927040-00002.
18. Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res 2012; 12:357-71; PMID:22812559; http://dx.doi.org/10.1586/erp.12.11.
19. Cairns JA. Valuing future benefits. Health Econ 1994; 3:221-9; PMID:7994322; http://dx.doi.org/10.1002/hec.4730030404.
20. Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics 2012; 30:337-53; PMID:22409292; http://dx.doi.org/10. 2165/11591560-000000000-00000.
21. Defechereux T, Paolucci F, Mirelman A, Youngkong S, Botten G, Hagen TP, et al. Health care priority setting in Norway a multicriteria decision analysis. BMC Health Serv Res 2012; 12:39; PMID:22335815; http://dx.doi.org/10.1186/1472- 6963-12-39.
22. Baltussen R, Stolk E, Chisholm D, Aikins M. Towards a multi-criteria approach for priority setting: an application to Ghana. Health Econ 2006; 15:689-96; PMID:16491464; http://dx.doi.org/10.1002/hec.1092.
23. Bloom DE, Canning D, Hu L, Liu Y, Mahal A, Yip W. The Contribution of Population Health and Demographic Change to Economic Growth in China and India. J Comp Econ 2010; 38:17-33; PMID:20419074; http://dx.doi.org/10.1016/j.jce.2009. 11.002.
24. Suhrke M, Mckee M. Re-orienting health systems. 2012. Ref Type: Report, eurohealthnet.eu/sites/.
25. Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma M. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics 2012; 30:681-95; PMID:22788259; http://dx.doi.org/10.2165/11597750-000000000-00000.
26. Davoodi H, Tiongson E, Asawanuchit S. Benefit Incidence of Public Education and Health Spending Worldwide: Evidence from a New Database. Poverty & Public Policy 2010; 2:191-238; http://dx.doi.org/10.2202/1944-2858.1055.
27. Kinderafdelingen ziekhuizen liggen overvol. KNACK 2012 Nov 23.